Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM.

Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. doi: 10.1002/acn3.214. Epub 2015 May 28.

2.

Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.

Narayanan KL, Chopra V, Rosas HD, Malarick K, Hersch S.

Mol Neurobiol. 2016 May;53(4):2132-40. doi: 10.1007/s12035-015-9147-9. Epub 2015 May 5.

3.

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM.

Neurology. 2014 Mar 11;82(10):850-7. doi: 10.1212/WNL.0000000000000187. Epub 2014 Feb 7.

4.

A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.

Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM.

Mov Disord. 2011 Aug 1;26(9):1691-7. doi: 10.1002/mds.23762. Epub 2011 May 24.

5.

Changes in dried blood spot Hb A1c with varied postcollection conditions.

Buxton OM, Malarick K, Wang W, Seeman T.

Clin Chem. 2009 May;55(5):1034-6. doi: 10.1373/clinchem.2008.111641. Epub 2009 Mar 19. No abstract available.

Supplemental Content

Loading ...
Support Center